Annual D&A
$13.69 M
-$25.45 M-65.02%
December 31, 2023
Summary
- As of February 7, 2025, RVNC annual depreciation & amortization is $13.69 million, with the most recent change of -$25.45 million (-65.02%) on December 31, 2023.
- During the last 3 years, RVNC annual D&A has risen by +$3.44 million (+33.59%).
- RVNC annual D&A is now -65.02% below its all-time high of $39.15 million, reached on December 31, 2022.
Performance
RVNC Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
Quarterly D&A
$1.25 M
-$177.00 K-12.39%
September 30, 2024
Summary
- As of February 7, 2025, RVNC quarterly depreciation & amortization is $1.25 million, with the most recent change of -$177.00 thousand (-12.39%) on September 30, 2024.
- Over the past year, RVNC quarterly D&A has dropped by -$873.00 thousand (-41.08%).
- RVNC quarterly D&A is now -93.19% below its all-time high of $18.38 million, reached on December 31, 2022.
Performance
RVNC Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM D&A
$6.08 M
-$873.00 K-12.55%
September 30, 2024
Summary
- As of February 7, 2025, RVNC TTM depreciation & amortization is $6.08 million, with the most recent change of -$873.00 thousand (-12.55%) on September 30, 2024.
- Over the past year, RVNC TTM D&A has dropped by -$24.57 million (-80.16%).
- RVNC TTM D&A is now -84.94% below its all-time high of $40.39 million, reached on March 31, 2023.
Performance
RVNC TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
RVNC Depreciation And Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -65.0% | -41.1% | -80.2% |
| 3 y3 years | +33.6% | -75.7% | -67.6% |
| 5 y5 years | +693.3% | +70.6% | +109.0% |
RVNC Depreciation And Amortization Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -65.0% | at low | -93.2% | at low | -84.9% | at low |
| 5 y | 5-year | -65.0% | +370.7% | -93.2% | +69.4% | -84.9% | +109.0% |
| alltime | all time | -65.0% | +847.6% | -93.2% | +263.9% | -84.9% | +1242.4% |
Revance Therapeutics Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.25 M(-12.4%) | $6.08 M(-12.6%) |
| Jun 2024 | - | $1.43 M(-27.9%) | $6.95 M(-23.2%) |
| Mar 2024 | - | $1.98 M(+39.6%) | $9.06 M(-33.9%) |
| Dec 2023 | $13.69 M(-65.0%) | $1.42 M(-33.2%) | $13.69 M(-55.3%) |
| Sep 2023 | - | $2.13 M(-39.8%) | $30.65 M(-17.8%) |
| Jun 2023 | - | $3.53 M(-46.6%) | $37.31 M(-7.6%) |
| Mar 2023 | - | $6.62 M(-64.0%) | $40.39 M(+3.2%) |
| Dec 2022 | $39.15 M(+97.2%) | $18.38 M(+109.2%) | $39.15 M(+49.5%) |
| Sep 2022 | - | $8.78 M(+32.9%) | $26.19 M(+16.1%) |
| Jun 2022 | - | $6.61 M(+22.9%) | $22.55 M(+7.5%) |
| Mar 2022 | - | $5.38 M(-0.8%) | $20.99 M(+5.7%) |
| Dec 2021 | $19.85 M(+93.7%) | $5.42 M(+5.2%) | $19.85 M(+5.9%) |
| Sep 2021 | - | $5.15 M(+2.1%) | $18.75 M(+7.9%) |
| Jun 2021 | - | $5.04 M(+18.9%) | $17.38 M(+26.4%) |
| Mar 2021 | - | $4.24 M(-1.8%) | $13.75 M(+34.2%) |
| Dec 2020 | $10.25 M(+252.4%) | $4.32 M(+14.3%) | $10.25 M(+53.3%) |
| Sep 2020 | - | $3.78 M(+167.4%) | $6.69 M(+83.6%) |
| Jun 2020 | - | $1.41 M(+91.2%) | $3.64 M(+20.6%) |
| Mar 2020 | - | $739.00 K(-2.4%) | $3.02 M(+3.8%) |
| Dec 2019 | $2.91 M(+68.5%) | $757.00 K(+3.1%) | $2.91 M(+10.7%) |
| Sep 2019 | - | $734.00 K(-7.1%) | $2.63 M(+12.4%) |
| Jun 2019 | - | $790.00 K(+25.8%) | $2.34 M(+19.0%) |
| Mar 2019 | - | $628.00 K(+32.2%) | $1.96 M(+13.8%) |
| Dec 2018 | $1.73 M | $475.00 K(+7.0%) | $1.73 M(+6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $444.00 K(+6.5%) | $1.62 M(+4.5%) |
| Jun 2018 | - | $417.00 K(+6.9%) | $1.55 M(+3.5%) |
| Mar 2018 | - | $390.00 K(+4.8%) | $1.50 M(+2.2%) |
| Dec 2017 | $1.47 M(+1.6%) | $372.00 K(-0.5%) | $1.47 M(-0.3%) |
| Sep 2017 | - | $374.00 K(+2.5%) | $1.47 M(+0.3%) |
| Jun 2017 | - | $365.00 K(+2.2%) | $1.47 M(+0.7%) |
| Mar 2017 | - | $357.00 K(-5.3%) | $1.46 M(+0.9%) |
| Dec 2016 | $1.45 M(-27.6%) | $377.00 K(+2.2%) | $1.45 M(-2.2%) |
| Sep 2016 | - | $369.00 K(+3.9%) | $1.48 M(-8.8%) |
| Jun 2016 | - | $355.00 K(+3.2%) | $1.62 M(-10.5%) |
| Mar 2016 | - | $344.00 K(-15.9%) | $1.81 M(-9.4%) |
| Dec 2015 | $2.00 M(-2.7%) | $409.00 K(-20.0%) | $2.00 M(-3.9%) |
| Sep 2015 | - | $511.00 K(-6.1%) | $2.08 M(-1.5%) |
| Jun 2015 | - | $544.00 K(+2.4%) | $2.11 M(+0.6%) |
| Mar 2015 | - | $531.00 K(+8.4%) | $2.09 M(+2.1%) |
| Dec 2014 | $2.05 M(+9.0%) | $490.00 K(-9.6%) | $2.05 M(-0.3%) |
| Sep 2014 | - | $542.00 K(+2.1%) | $2.06 M(+3.4%) |
| Jun 2014 | - | $531.00 K(+8.8%) | $1.99 M(+3.9%) |
| Mar 2014 | - | $488.00 K(-1.6%) | $1.92 M(+1.9%) |
| Dec 2013 | $1.88 M(+5.9%) | $496.00 K(+4.4%) | $1.88 M(+35.8%) |
| Sep 2013 | - | $475.00 K(+3.9%) | $1.39 M(+52.2%) |
| Jun 2013 | - | $457.00 K(+0.9%) | $910.00 K(+100.9%) |
| Mar 2013 | - | $453.00 K | $453.00 K |
| Dec 2012 | $1.78 M(-10.4%) | - | - |
| Dec 2011 | $1.98 M | - | - |
FAQ
- What is Revance Therapeutics annual depreciation & amortization?
- What is the all time high annual D&A for Revance Therapeutics?
- What is Revance Therapeutics annual D&A year-on-year change?
- What is Revance Therapeutics quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Revance Therapeutics?
- What is Revance Therapeutics quarterly D&A year-on-year change?
- What is Revance Therapeutics TTM depreciation & amortization?
- What is the all time high TTM D&A for Revance Therapeutics?
- What is Revance Therapeutics TTM D&A year-on-year change?
What is Revance Therapeutics annual depreciation & amortization?
The current annual D&A of RVNC is $13.69 M
What is the all time high annual D&A for Revance Therapeutics?
Revance Therapeutics all-time high annual depreciation & amortization is $39.15 M
What is Revance Therapeutics annual D&A year-on-year change?
Over the past year, RVNC annual depreciation & amortization has changed by -$25.45 M (-65.02%)
What is Revance Therapeutics quarterly depreciation & amortization?
The current quarterly D&A of RVNC is $1.25 M
What is the all time high quarterly D&A for Revance Therapeutics?
Revance Therapeutics all-time high quarterly depreciation & amortization is $18.38 M
What is Revance Therapeutics quarterly D&A year-on-year change?
Over the past year, RVNC quarterly depreciation & amortization has changed by -$873.00 K (-41.08%)
What is Revance Therapeutics TTM depreciation & amortization?
The current TTM D&A of RVNC is $6.08 M
What is the all time high TTM D&A for Revance Therapeutics?
Revance Therapeutics all-time high TTM depreciation & amortization is $40.39 M
What is Revance Therapeutics TTM D&A year-on-year change?
Over the past year, RVNC TTM depreciation & amortization has changed by -$24.57 M (-80.16%)